Chapter 1: Executive Summary

1.1 How the Market Views the Company

The market views FormFactor as the "exclusive supplier of HBM probe cards"—a direct beneficiary of the AI CapEx supercycle. Here, HBM (High Bandwidth Memory) is the most critical high-speed memory in AI training and inference servers, typically packaged with GPUs/AI accelerators to address bandwidth bottlenecks in large model training. The core logic of this narrative is: each generation upgrade of HBM (HBM3→HBM4→HBM5) implies more and more expensive probe cards, and FORM is the technology leader in MEMS (Micro-Electro-Mechanical Systems—a technology for manufacturing micron-scale probes using semiconductor photolithography processes) probe cards, enjoying an exclusive supply position. The variables the market focuses on are HBM shipment growth rate, probe card content per wafer (the value of probe cards required per wafer), and the gross margin expansion trajectory (39%→45%→47% target). With a Forward P/E of 71x and EV/Sales of 12.7x, the market is pricing in "the company after HBM4 fully takes off," not the company today.

If FORM were truly a monopolist in HBM consumables—fast-growing, highly profitable, and with a deep moat—then 12.7x EV/Sales would not be unreasonable. The problem is: this narrative cannot explain four facts.

1.2 What the Old Narrative Fails to Explain

Fact One: ROIC (Return on Invested Capital—a measure of how much profit is earned for every dollar invested) is only 4.9%, significantly below WACC (Weighted Average Cost of Capital—the minimum return investors require) of approximately 9%. The market is paying 12.7x EV/Sales for a business whose capital returns do not yet cover its cost of capital.

Fact Two: Foundry & Logic (foundry and logic chips—a general term for non-memory chips) revenue decreased from $436M in FY2021 to $370M in FY2025, a 15% decline. Concurrently, Technoprobe (an Italian probe card manufacturer and FORM's most direct international competitor in advanced logic probe cards) significantly increased its penetration in the advanced logic segment (industry channel information points to approximately 30% share, though Technoprobe's official materials have not directly confirmed this figure). FORM is not "walking on two legs"; its high-margin leg is shrinking.

Fact Three: Full-year FY2025 EPS of $0.69—even after excluding the $73M one-time investment gain in FY2023 (pre-tax proceeds from the sale of the FRT business to Camtek), normalized EPS went from ~$0.70 to $0.69, showing virtually zero growth over two years, while revenue grew by 18%. Growth has not translated into profit.

Fact Four: Sell-side analysts' median target price of $80-86 vs. current $128—100% of covering sell-side analysts believe the stock is overvalued by 33%+. The rating distribution of 6 Hold + 4 Buy + 0 Sell indicates that sell-side analysts generally believe the current price already incorporates an overly optimistic outlook.

If FORM continues to be viewed as an "HBM consumable monopolist," these four contradictions would be smoothed over—low ROIC would be explained away by "investment cycle," F&L contraction would be masked by "HBM growth compensation," and stagnant EPS would be diluted by "one-time factors."

1.3 What We Believe It Truly Is

FORM is not a monopolistic supplier of HBM consumables, but rather a cyclical stock with an HBM narrative premium—where growth direction and profit direction are structurally opposite, and approximately $30-50 of the $128 share price is an HBM narrative premium rather than fundamental value.

This means that what truly determines FORM's valuation is not HBM content per wafer (the market's default variable), but rather gross margin sustainability (our primary variable). Specifically, it's a two-pronged assessment: whether non-GAAP GM can consistently be ≥45% (operational quality), and whether the GAAP↔non-GAAP gap (which abruptly widened from 1.7pp to 11pp in Q1, primarily due to acquisition amortization) will narrow (accounting burden). Because: the market has fully priced in optimistic expectations for HBM demand (SK Hynix's 2026 capacity 100% sold out, DRAM CapEx +23% are all public information), but whether GM can consistently improve to non-GAAP 45%+ and GAAP is not dragged down to the 30%+ range by amortization, will determine if ROIC can exceed WACC—this is the real watershed between $128 and $65.

The valuation method shifts from Forward non-GAAP P/E (market uses $2.50 FY2027E × 50x = $125) to Owner P/E on Owner Earnings (actual profits available to shareholders). FY2025 Owner Earnings were only approximately $18M (GAAP Net Income $54M + D&A $37.6M - Maintenance CapEx $35M - SBC $39M; here, SBC is treated as an economic cost deduction because SBC dilution is real and FORM's SBC/Revenue is 4.9%), corresponding to an Owner P/E of approximately 560x for a $10B market cap. Even with an optimistic FY2027 forecast ($140M OE), an Owner P/E of 71x still nearly doubles that of the industry's highest quality company, ASML, which has a 10-year average of 35-40x.

1.4 Rating and Valuation Boundaries

Rating: Cautious Watch (High Uncertainty) [Expensive × Direction Unconfirmed × Has Catalysts]

Black box ratio 40% (HBM customer internal test strategies, JEDEC SP-HBM4 standard adoption progress, and Farmers Branch actual utilization are all unobservable variables), complexity 4/5—no single point fair value provided.

Four Scenario Probability-Weighted :

Probability-Weighted Range: $70-100 (Weighted Expected Value approx. $91). Current $128 is overvalued by approximately 30-45%.

5 top investors with independent perspectives (Value Investing / Global Macro / Trend Trading / Short Seller Prosecutor / Variable Purification) unanimously believe that $128 lacks a margin of safety. 5/5 recommend Cautious Watch, 0/5 recommend Buy.

Poor Convexity: Even if the bull case fully materializes, upside potential is only +2% to $130; base case downside is 22-38%, bear case downside is 45-57%. The upside/downside asymmetry ratio (N/M ratio—a metric measuring long odds) is only 0.17, far below the long threshold of 1.0.

A precise fair value is a low-confidence judgment—a 40% black box means nearly half of the variables in our valuation model cannot be directly observed. However, the current price does not offer a margin of safety, which is a high-confidence judgment—5 valuation methods, 5 independent perspectives, and all sell-side coverage collectively point to overvaluation.

1.5 Summary

Chapter 2: Why Research FormFactor Now

2.1 Core Investment Question

FormFactor’s stock price has risen from $24 to $128 (+433%) over the past 12 months, reaching a market capitalization of $10B. Is a semiconductor equipment company with ROIC below WACC worth pricing at a Forward P/E of 71x? This is not a question of "Is there demand for HBM?" (the answer is clearly yes), but rather "Who benefits from HBM demand, at what speed will profits materialize, and at what valuation multiple is there still a margin of safety?"

2.2 Why Now

Three time windows converge within the next 30 days:

1. April 29 Q1 FY2026 Earnings Report — Q1 guidance for non-GAAP GM is 45% (historical high), but GAAP GM is only 34% (gap shifted abruptly from 1.7pp to 11pp). The nature of this gap determines the definition of the key variable.
2. May 11 Analyst Day — Management will release an updated Target Model (currently $850M/47% GM/22% OPM). An upward revision or maintenance will reshape market expectations, while a downward revision will accelerate value reversion.
3. DRAM CapEx Cycle — Gartner forecasts a 14% correction in DRAM prices in Q3 2026. If price signals weaken, the cyclical window will close earlier than market expectations.

2.3 Market Implied Beliefs

The $128 stock price implies the following set of beliefs (derived from Reverse DCF):

• HBM demand sustained for ≥3 years, DRAM probe card revenue annually increasing by 25-30%
• Non-GAAP gross margin continuously improves from 40.8% to 47%, while the GAAP↔non-GAAP gap narrows
• Farmers Branch new production line FY2027 utilization >75%, contributing 3.5-4pp to GM
• ROIC crosses WACC 9% from the current 4.9% — all the above conditions must hold simultaneously
• Target Model ($850M/47% GM/22% OPM) fully achieved, with a joint probability in the low double digits

2.4 Falsifiable Hypotheses

H1 (Core): FORM's HBM growth cannot simultaneously improve ROIC, because the direction of growth (low-GM DRAM) is structurally opposite to the direction of profit (high-GM F&L). Verification condition: non-GAAP GM ≥45% for 4 consecutive quarters AND GAAP↔non-GAAP gap narrows to ≤5pp AND ROIC>WACC.

H2 (Supporting): Based on current model estimates, the IRR for Farmers Branch investment is approximately 8.1%, which is below WACC 9% — if this estimate holds true, growth CapEx poses a risk of value erosion (Note: 8.1% is our model's estimate, without external validation). Falsification condition: ROIC >12% for 2+ years after FB reaches full capacity.

H3 (Competition): Technoprobe's market share erosion in F&L is structural (not cyclical), and FORM's probe card business is shifting from technological leadership to cost competition. Falsification condition: FY2027 F&L revenue recovers to $400M+.

2.5 Decisive Variables (Ranked by Explanatory Power)

Chapter 3: Core Controversy: Structural Opposition Between Growth Direction and Profit Direction

3.1 What the Market is Buying

FormFactor’s stock price has risen from $24 to $128 (+433%) over the past 12 months, with clear market pricing logic: each generation upgrade of HBM (High Bandwidth Memory – high-speed memory chips used for AI training) requires more and more expensive probe cards. The HBM4 interface increases from 1,024 to 2,048 data signals, meaning a doubling of pin count implies a doubling of probe card complexity and value. SK Hynix's HBM capacity for 2026 is 100% sold out, and industry-wide DRAM CapEx is up 23% to $60.5B.

This narrative is real – we do not deny the strength of HBM demand. Our question is: Does demand strength equal profit strength, and does profit strength support the current valuation?

3.2 Four Cracks in the Old Map

Crack One: Revenue Growth Without Profit Growth. From FY2023 to FY2025, revenue grew from $663M to $785M (+18.4%). But normalized EPS (after excluding a one-time investment gain of $73M in FY2023) went from approximately $0.70 to $0.69 – zero growth over two years. The fastest-growing category (DRAM/HBM probe cards) happens to be the lowest-gross-margin category. The original 10-K text confirms: "DRAM products generally have lower margins than Foundry & Logic products." DRAM's share of Probe Card revenue increased from 22.9% in FY2023 to 38.8% (+15.9pp), with lower-margin products replacing higher-margin products, completely eroding revenue growth through margin dilution. Simultaneously, CapEx surged from $56M to $104M (investment in the new Farmers Branch production line), and depreciation increased from $33M to $37.6M (and will continue to rise as FB capacity is capitalized), further compressing EPS.

Crack Two: ROIC Consistently Below WACC.

FY2021 was the only year ROIC exceeded WACC (9.8%), coinciding with the peak of the semiconductor upcycle. Since then, ROIC has been < WACC for 4 consecutive years. Unless FY2027 ROIC surpasses 9% (requiring $850M+ revenue × 45%+ GM simultaneously), a 12.7x EV/Sales valuation prices a company whose capital returns consistently fall below its cost of capital.

Crack 3: Structural Loss in Foundry & Logic. Foundry & Logic revenue declined from $436M in FY2021 to $370M in FY2025 (-15%), while Technoprobe (FORM's core competitor in advanced logic probe cards) simultaneously increased its penetration in advanced logic (industry channels estimate ~30% market share, specific figures unconfirmed by primary company materials [Confidence Level B]). The revenue structure is shifting from diversified (F&L multiple customers) to concentrated (DRAM few customers), indicating declining growth quality.

Crack 4: Sell-side collectively estimates 33%+ downside. 6 Hold + 4 Buy + 0 Sell, median price target $80-86.

3.3 FY2024→FY2025 Real Growth Rate: 2.8%

The FY2023→FY2025 comparison (+18.4%) benefits from a low base effect (FY2023 was a cyclical trough at $663M). A more realistic growth rate is FY2024→FY2025: revenue increased from $764M to $785M, a mere 2.8% increase.

10-K Precise Segment Breakdown:

DRAM/HBM contributed $20M (95%) of the $21M increase, but Probe Cards as a whole grew by only 1.9%—severely inconsistent with the "HBM high growth" narrative. DRAM growth of 8.9% is far below the "doubling" imagined by the market.

FY2024→FY2025: Revenue growth 2.8%, Share price YoY growth 180% ($45.9→$127.68). This is purely valuation multiple expansion, not fundamentally driven.

3.4 Annual Perspective: FORM's True Growth Profile

Viewed over a 5-year horizon, the "HBM high growth" narrative becomes even less tenable :

The 5-year Revenue CAGR of +0.5% vs. WFE industry +10-15% indicates that FORM not only failed to outperform the industry but even lagged inflation. NOPAT and EPS are both declining; the only metric that increased is the share price. The increase from $38 to $128 entirely stems from valuation multiple expansion (P/E from 36x to 185x), not earnings growth.

As the 5-year horizon covers a complete semiconductor cycle (2021 cyclical peak → 2022-2023 downturn → 2024-2025 upturn), FORM's zero-growth profile is not cyclical—it reflects structural business issues. Peers (KLAC/LRCX/AMAT) achieved double-digit revenue and profit CAGRs during the same period, demonstrating that the problem lies not with the industry, but with FORM itself.

This 5-year data set is the strongest evidence to refute the narrative that "HBM has transformed FORM": The impact of HBM only began to manifest in FY2024-2025, but even with HBM's incremental contribution, the 5-year CAGR remains zero. This implies that HBM growth merely compensated for the contraction in other segments (F&L/Systems) rather than creating net incremental growth. The market is paying 12.7x EV/Sales for "HBM incremental growth," yet overlooks that this HBM incremental growth has been offset by contractions in other segments.

3.5 Why Growth and Profit Directions Are Structurally Opposed

This chart reveals FORM's core dilemma: its growth engine (DRAM/HBM) and profit engine (F&L) are moving in opposite directions. The tension will persist unless one of the following occurs: ① HBM4/5 ASP premium drives DRAM GM close to F&L levels ② Economies of scale at Farmers Branch allow fixed cost absorption to offset mix headwinds ③ F&L stabilizes or rebounds in the next-generation process node (depending on the evolution of the competitive landscape).

Current GM data is indeed improving: Q4 FY2025 GAAP GM was 42.2%, with Q1 FY2026 guidance for non-GAAP 45%±1.5% (GAAP 34%±1.5%, the gap surging to ~11pp due to acquisition amortization). However, FORM's GAAP GM > 42% has only occurred three times in the past 20 quarters (Q3'21 42.7%, Q4'21 42.1%, Q4'25 42.2%)—each time representing a cycle peak, not a new normal. The Q1 earnings report on April 29th will be the first hard data point to validate "new normal vs. cycle peak" and will also reveal the precise composition of the GAAP↔non-GAAP gap for the first time.